OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

August 7th 2020

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma

August 7th 2020

Jonathan C. Trent, MD, PhD, discusses the role of circulating tumor DNA in soft tissue sarcoma.

Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera

August 7th 2020

Ronald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.

Dr. Choueiri on the Impact of the COVID-19 Pandemic on Treatment in RCC

August 7th 2020

Toni K. Choueiri, MD, discusses the impact the coronavirus disease 2019 pandemic has had on diagnosing and treating patients with renal cell carcinoma.

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

August 7th 2020

Sara A. Hurvitz, MD, discusses the lack of predictive biomarkers in HER2-positive breast cancer.

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Dr. Raje on Efficacy With Melflufen in Triple-Refractory Myeloma

August 6th 2020

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Dr. Ahmed on Remaining Questions With Tucatinib in Breast Cancer Brain Metastases

August 6th 2020

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

Dr. Abid on Challenges With CAR T-Cell Therapy During the COVID-19 Pandemic

August 6th 2020

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

Dr. Costa on Unmet Needs in Relapsed/Refractory Multiple Myeloma

August 6th 2020

Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.

Dr. Schwartz on Results From the GIST Cohort in the Alliance A091401 Trial

August 6th 2020

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Dr. Czerniecki on the Benefit of Tucatinib in HER2+ Breast Cancer and Brain Metastases

August 6th 2020

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC

August 6th 2020

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Mascarenhas on Approved and Emerging Treatment Options in Myelofibrosis

August 6th 2020

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

Dr. Lonial on the FDA Approval of Belantamab Mafodotin-blmf in Multiple Myeloma

August 6th 2020

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Dr. Roland on the Safety of Neoadjuvant Checkpoint Blockade in Sarcoma

August 5th 2020

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma

August 5th 2020

Christian U. Blank, MD, PhD, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

August 5th 2020

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Raje on Remaining Questions in Multiple Myeloma

August 5th 2020

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma.

Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

August 5th 2020

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.